Free Trial

Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics logo
$1.48 -0.09 (-5.73%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.51 +0.03 (+2.03%)
As of 10/17/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OVID vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEM

Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

Ovid Therapeutics vs. Its Competitors

Ovid Therapeutics (NASDAQ:OVID) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Inhibrx Biosciences has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -574.44%. Ovid Therapeutics' return on equity of -58.87% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid Therapeutics-574.44% -58.87% -43.18%
Inhibrx Biosciences N/A -137.83%-76.31%

Inhibrx Biosciences has lower revenue, but higher earnings than Ovid Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$6.65M15.82-$26.43M-$0.53-2.79
Inhibrx Biosciences$200K2,696.90$1.69B-$10.58-3.52

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ovid Therapeutics presently has a consensus price target of $3.70, suggesting a potential upside of 150.00%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Ovid Therapeutics is more favorable than Inhibrx Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Inhibrx Biosciences
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Ovid Therapeutics' average media sentiment score of 0.00 equaled Inhibrx Biosciences'average media sentiment score.

Company Overall Sentiment
Ovid Therapeutics Neutral
Inhibrx Biosciences Neutral

Ovid Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$105.24M$3.44B$6.19B$10.56B
Dividend YieldN/A2.27%5.70%4.81%
P/E Ratio-2.7923.0185.5427.13
Price / Sales15.82481.75608.39130.24
Price / CashN/A46.9237.1060.81
Price / Book1.5410.4112.236.52
Net Income-$26.43M-$52.77M$3.33B$276.93M
7 Day Performance-11.38%2.31%1.17%1.93%
1 Month Performance22.31%12.59%6.85%2.19%
1 Year Performance21.31%11.18%58.93%34.62%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVID
Ovid Therapeutics
3.9844 of 5 stars
$1.48
-5.7%
$3.70
+150.0%
+21.3%$105.24M$6.65M-2.7960
INBX
Inhibrx Biosciences
1.6506 of 5 stars
$34.38
+5.9%
N/A+132.8%$470.27M$200K-3.25166
ATXS
Astria Therapeutics
1.9211 of 5 stars
$8.47
+1.9%
$29.50
+248.3%
+4.5%$468.97MN/A-4.2130Trending News
Analyst Downgrade
CYRX
CryoPort
3.2917 of 5 stars
$9.40
+1.1%
$12.56
+33.6%
+34.0%$465.62M$228.38M7.071,186News Coverage
SLDB
Solid Biosciences
2.997 of 5 stars
$6.01
+0.8%
$15.00
+149.6%
-10.9%$464.10M$8.09M-2.15100News Coverage
Analyst Downgrade
ALMS
Alumis
3.432 of 5 stars
$4.61
+3.8%
$20.17
+337.5%
-62.7%$462.05MN/A0.00N/APositive News
Gap Down
DRUG
Bright Minds Biosciences
3.22 of 5 stars
$64.97
+2.7%
$81.00
+24.7%
+33.7%$445.81MN/A-69.86N/APositive News
LXEO
Lexeo Therapeutics
3.0481 of 5 stars
$8.20
-0.5%
$17.00
+107.3%
-13.8%$444.97M$650K-2.5258Trending News
Analyst Forecast
Insider Trade
RAPT
Rapt Therapeutics
3.1558 of 5 stars
$26.35
-1.6%
$24.78
-6.0%
+104.9%$443.05M$1.53M-1.8680Analyst Revision
Gap Down
AUTL
Autolus Therapeutics
3.5538 of 5 stars
$1.65
-0.6%
$9.12
+452.7%
-66.3%$441.80M$10.12M-1.96330
CGEM
Cullinan Therapeutics
3.5628 of 5 stars
$7.83
+5.8%
$26.00
+232.1%
-53.1%$437.15MN/A-2.4230News Coverage
Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:OVID) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners